protein intake optimization glp-1 receptor agonists Optimizing therapies for obesity and diabetes management GLP-1 agonists and changes in
Description
(14 September 2021, date last accessed)
PMID 29439603
Ileus (Intestinal Obstruction) In rare cases, ileus, where intestinal movement stops, can occur
In 2025 analysts widely agreed Lilly had emerged as the leading player in obesity treatments ( [14] ) ( [19] )
Glynnis Page, OMS 2026 Rocky Vista University College of Osteopathic Medicine DOI: 10.70709/r2fykae2uu Abstract Background The use of glucagon-like peptide-1 receptor agonists (GLP-1s) has surged in response to the growing prevalence of type 2 diabetes mellitus and obesitytwo conditions that are known to elevate the risk of perioperative complications in orthopedic surgery
